Offered through CNS|CRO

Successful drug development programs require animal models that more faithfully replicate the human disease condition

Advantages of CNS|CRO’s Animal Models

– Slowly progressing, more accurately replicate the course of human disease progression –

– Behavioural characteristics and pathologies associated with human disease progression –

– Ideal for identification of early stage treatments –

CNS|CRO (http://www.cnscro.ca), a wholly-owned subsidiary of Neurodyn Inc., is a pre-clinical contract research organization offering a suite of Animal Models of neurological disease that are proprietary, highly predictive, slowly developing and environmentally based.

Neurological disease is a large and growing problem despite billions of research dollars. Most current animal models only replicate a single aspect of a disease. Successful drug development programs require animal models that more faithfully replicate the human disease condition

Models

  • Parkinson’s ALS – Developed from a human disease cluster, environmentally based, allows for the study of the candidate therapeutics through-out the complete disease development cycle.
  • Epilepsy – Neuro-developmental in origin, slowly developing, progressive model remarkable correlation with many features of clinical TLE in humans This is NOT a model of convulsions.
  • Schizophrenia – Non-invasive chemical manipulation of perinatal brain development resulting in delayed-onset appearance of behavioural deficits and changes in cortical dopaminergic markers consistent with human Schizophrenia.
  • Stroke – Test animals can be studied for up to 2 months providing extensive behavioural testing for a more complete evaluation of a test compound’s effectiveness and potential for post stroke recovery.  This stroke model was used to generate pre-clinical data for a drug candidate that has successfully completed Phase II clinical trial, confirming the models viability as a highly predictive research tool.

Additional Services

  • Standard models of neurological disease,
  • Behavioural testing,
  • In vitro assays

For additional information, visit: www.cnscro.ca

Or contact:   Dr. Denis Kay   902-314 0776 (mobile)  dgkay@neurodyn.ca